SIGMAR1 and cancer: In this connection, our findings offer, for the first time, experimental evidence suggesting that SIGMAR1 modulators represent a novel class of therapeutic agents with the potential to revolutionize PD-L1/PD-1 blockade strategies in cancer immunotherapy.